Related references
Note: Only part of the references are listed.Human papillomavirus infection and seroprevalence among female university students in Mexico
Alexander Pedroza-Gonzalez et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2022)
Genotyping of human papillomavirus DNA in Wielkopolska region
Marcin Przybylski et al.
GINEKOLOGIA POLSKA (2022)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Serum and cervicovaginal IgG immune responses against α7 and α9 HPV in non-vaccinated women at risk for cervical cancer: Implication for catch-up prophylactic HPV vaccination
Ralph-Sydney Mboumba Bouassa et al.
PLOS ONE (2020)
Significance of serum antibodies against HPV E7, Hsp27, Hsp20 and Hp91 in Iranian HPV-exposed women
Amitis Ramezani et al.
BMC INFECTIOUS DISEASES (2019)
Development of an in-house ELISA to detect anti-HPV16-L1 antibodies in serum and dried blood spots
Ramya Bhatia et al.
JOURNAL OF VIROLOGICAL METHODS (2019)
Ten Years of Human Papillomavirus Vaccination in the United States
Lauri E. Markowitz et al.
ACADEMIC PEDIATRICS (2018)
Immunogenicity and Safety of a 9-Valent HPV Vaccine
Pierre Van Damme et al.
PEDIATRICS (2015)
Characteristics of HPV-Specific Antibody Responses Induced by Infection and Vaccination: Cross-Reactivity, Neutralizing Activity, Avidity and IgG Subclasses
Mirte Scherpenisse et al.
PLOS ONE (2013)
Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis
Talia Malagon et al.
LANCET INFECTIOUS DISEASES (2012)
Kinetic and HPV infection effects on cross-type neutralizing antibody and avidity responses induced by Cervarix®
Troy J. Kemp et al.
VACCINE (2012)
Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine up to 8.4 years of follow-up
Cecilia M. Roteli-Martins et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2012)
Genital human Papillomavirus infection in patients with autoimmune inflammatory diseases
Francois Aubin et al.
JOINT BONE SPINE (2011)
Serum Antibody Response Following Genital α9 Human Papillomavirus Infection in Young Men
Zoe R. Edelstein et al.
JOURNAL OF INFECTIOUS DISEASES (2011)
Human papillomaviruses in oral carcinoma and oral potentially malignant disorders: a systematic review
S. Syrjanen et al.
ORAL DISEASES (2011)
Neutralization of non-vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera
Eve Draper et al.
VACCINE (2011)
Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: A meta-analysis
Hugo De Vuyst et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Epidemiology of Human Papillomavirus Infection in Men, Cancers other than Cervical and Benign Conditions
Anna R. Giuliano et al.
VACCINE (2008)
Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women:: an interim analysis of a phase III double-blind, randomised controlled trial
Jorma Paavonen et al.
LANCET (2007)
High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up
L. L. Villa et al.
BRITISH JOURNAL OF CANCER (2006)
Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: Results from a population-based study in Costa Rica
RP Viscidi et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2004)
Natural history of human papillomavirus type 16 virus-like particle antibodies in young women
GYF Ho et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2004)
The causal relation between human papillomavirus and cervical cancer
FX Bosch et al.
JOURNAL OF CLINICAL PATHOLOGY (2002)
Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine
CD Harro et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2001)
Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection
JJ Carter et al.
JOURNAL OF INFECTIOUS DISEASES (2000)
Specific serum IgG, IgM and IgA antibodies to human papillomavirus types 6, 11, 16, 18 and 31 virus-like particles in human immunodeficiency virus-seropositive women
A Petter et al.
JOURNAL OF GENERAL VIROLOGY (2000)
Share Paper
